Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Accumulated Expenses (2019 - 2023)

Alx Oncology Holdings' Accumulated Expenses history spans 4 years, with the latest figure at $2.1 million for Q1 2023.

  • For Q1 2023, Accumulated Expenses changed N/A year-over-year to $2.1 million; the TTM value through Mar 2023 reached $2.1 million, changed N/A, while the annual FY2022 figure was $18.6 million, 464.72% up from the prior year.
  • Accumulated Expenses for Q1 2023 was $2.1 million at Alx Oncology Holdings, down from $18.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $18.6 million in Q4 2022 and bottomed at $671000.0 in Q2 2020.
  • The 4-year median for Accumulated Expenses is $2.1 million (2023), against an average of $5.3 million.
  • The largest annual shift saw Accumulated Expenses skyrocketed 66.87% in 2021 before it surged 464.72% in 2022.
  • A 4-year view of Accumulated Expenses shows it stood at $2.0 million in 2020, then surged by 66.87% to $3.3 million in 2021, then soared by 464.72% to $18.6 million in 2022, then crashed by 88.85% to $2.1 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Accumulated Expenses are $2.1 million (Q1 2023), $18.6 million (Q4 2022), and $3.3 million (Q4 2021).